The U.S. Food and Drug Administration has expanded its approval of Dysport (abobotulinumtoxinA) as a treatment for spasticity in adults from not just the upper limbs but to the lower limbs as well, according to its maker, Ipsen Biopharmaceuticals. Spasticity can affect those with amyotrophic lateral sclerosis (ALS), multiple sclerosis, cerebral…
News
Stem cell transplantation in patients with amyotrophic lateral sclerosis (ALS) has the potential to be “an important alternative strategy” in treating the disease, a new study suggests. In recent decades, many advances in identifying and understanding the underlying mechanisms of ALS have been made. But those advances have not resulted in…
News
ALS Patients Experience Inefficient Skeletal Muscle Oxidative Function During Exercise, Study Finds
A new study shows that patients with amyotrophic lateral sclerosis (ALS) experience decreased oxidative metabolism during exercise, and that differences among individuals in exercise capacity matches ALS clinical heterogeneity. The study, titled, “Inefficient skeletal muscle oxidative function…
AveXis and REGENXBIO have signed a new licensing agreement to develop therapies for a particular form of ALS and for Rett syndrome. They already have an agreement that covers spinal muscular atrophy therapies. The form of amyotrophic lateral sclerosis that the new agreement covers is the one caused by mutations…
ALS patients compensate for neuron loss in some brain regions by stepping up activity in other regions, according to a study. The finding suggests that analyzing patients’ brain networks could help doctors determine the state of their disease and monitor its progression. The study, “Functional reorganization during cognitive function…
People dying of terminal diseases like amyotrophic lateral sclerosis (ALS) and inmates on death row have something in common: their outlooks are more positive than might be expected. A recent study examining attitudes on impending death, “Dying is Unexpectedly Positive,” appeared in the journal Psychological Science. Death is an important part…
Flex Pharma, which develops therapies to reduce the cramps and shaking that are hallmarks of ALS and other neurological diseases, has a new CEO. Dr. William McVicar, head of the company’s research and development arm, will assume the interim chief executive’s post on July 3. He replaces Dr. Christoph Westphal, who…
American Airlines has raised more than $800,000 at its second annual American Airlines Charity Golf Tournament to support the research initiative Answer ALS. The tournament and a fund-raising auction took place in American’s home base of Dallas, May 24 and 25. “We are proud to partner with Answer ALS…
Insilico Medicine has launched ALS.AI, a drug discovery platform for new amyotrophic lateral sclerosis (ALS) treatments. It uses a powerful new analytical approach involving “deep learning” to seek out new therapies for the disease — and to evaluate whether existing drugs used to treat other diseases can be repurposed for treating ALS.
ProMIS Neurosciences hopes to develop an ALS therapy around a component of a protein that is faulty in the disease. The TDP43 protein’s abnormality leads to it becoming misfolded — that is, it not having a normal structure — in both amyotrophic lateral sclerosis and frontotemporal dementia (FTD). ProMIS thinks it can eliminate…
Recent Posts
- $1 million grant supports trial of experimental treatment for ALS
- Higher physical activity tied to lower ALS risk in large UK study
- Those earlier years with ALS seem like a different life
- Frailty-based screening tool may help flag people at higher risk of ALS
- How I learned to live — and thrive — with ALS